Patents by Inventor Soren Aasmul

Soren Aasmul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240358250
    Abstract: The technology relates to video laryngoscopes with improved illumination. An example laryngoscope includes a display; a handle; an arm extending distally from the handle; a camera positioned at a distal end of the arm; a light source positioned at the distal end of the arm; and a unibody plug positioned at the distal end of the arm, the unibody plug. The unibody plug includes a light guide formed of a solid transparent material having an entry surface at a proximal end of the light guide and an exit surface at a distal end of the light guide, wherein the entry surface is adjacent the light source; and a frame that defines an air gap around at least 70% of a length of the light guide.
    Type: Application
    Filed: April 1, 2024
    Publication date: October 31, 2024
    Applicant: Covidien LP
    Inventors: Juergen Van Vlem, Yik Loong Tham, Soren Aasmul
  • Publication number: 20240252068
    Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.
    Type: Application
    Filed: March 19, 2024
    Publication date: August 1, 2024
    Inventors: Rajiv V. Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
  • Patent number: 11931145
    Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: March 19, 2024
    Assignee: MEDTRONIC MINIMED, INC.
    Inventors: Rajiv Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
  • Publication number: 20220087578
    Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.
    Type: Application
    Filed: December 6, 2021
    Publication date: March 24, 2022
    Inventors: Rajiv Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
  • Patent number: 11229384
    Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 25, 2022
    Assignee: MEDTRONIC MINIMED, INC.
    Inventors: Rajiv Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
  • Patent number: 10864286
    Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: December 15, 2020
    Assignee: Medtronic MiniMed, Inc.
    Inventors: Tri T. Dang, Soren Aasmul, Jesper Svenning Kristensen, Joseph Hanna, Robert McKinlay
  • Patent number: 10792378
    Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: October 6, 2020
    Assignee: Medtronics MiniMed, Inc.
    Inventors: Soren Aasmul, Jesper Svenning Kristensen
  • Publication number: 20200171173
    Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 4, 2020
    Applicant: Medtronic MIniMed, Inc.
    Inventors: Tri T. Dang, Soren Aasmul, Jesper Svenning Kristensen, Joseph Hanna, Robert McKinlay
  • Patent number: 10543288
    Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: January 28, 2020
    Assignee: MEDTRONIC MINIMED, INC.
    Inventors: Tri T. Dang, Soren Aasmul, Jesper Svenning Kristensen, Joseph Hanna, Robert McKinlay
  • Publication number: 20190246926
    Abstract: The invention relates to a device for detecting atrial fibrillation of a subject, comprising a member comprising —mechanical connection means to wearably connect the member to a subject; —the member further comprising an optical sensor arranged to measure a signal representing a blood perfusion parameter of the subject; the member comprising the optical sensor and mechanical connection means at such relative positions that when the mechanical connection means connect the member to the subject, the optica! sensor operatively faces the subject. The device is arranged to detect atrial fibrillation of the subject based on the signal measured by the optical sensor.
    Type: Application
    Filed: June 22, 2017
    Publication date: August 15, 2019
    Inventors: Nathalie Virag, Soren Aasmul, Catherine Chassard, Richard Cornelussen, Gerard Hill, Robert Leinders, Mirko De Melis, Raphael Schneider, Vasiliki Spyropoulou
  • Publication number: 20190117137
    Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.
    Type: Application
    Filed: November 29, 2018
    Publication date: April 25, 2019
    Inventors: RAJIV SHAH, JESPER SVENNING KRISTENSEN, KATHERINE T. WOLFE, SOREN AASMUL, ANUBHUTI BANSAL
  • Patent number: 10194845
    Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: February 5, 2019
    Assignee: MEDTRONIC MINIMED, INC.
    Inventors: Rajiv Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
  • Publication number: 20180311383
    Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 1, 2018
    Applicant: Medtronic MiniMed, Inc.
    Inventors: Soren Aasmul, Jesper Svenning Kristensen
  • Publication number: 20180311382
    Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 1, 2018
    Applicant: Medtronic MiniMed, Inc.
    Inventors: Tri T. Dang, Soren Aasmul, Jesper Svenning Kristensen, Joseph Hanna, Robert McKinlay
  • Patent number: 9936905
    Abstract: A device for detection or measurement of a carbohydrate analyte in fluid comprises: an optical sensor comprising components of an assay for carbohydrate analyte, the readout of which is a detectable or measurable optical signal, and a light guide having a distal portion optically coupled to the assay components and a proximal portion; and a reader for interrogating the optical sensor, the reader comprising an assay interrogating system including a lens; and an interface portion forming part of at least one of the optical sensor and the reader, the interface portion being capable of removably constraining the proximal portion of the light guide and the lens of the assay interrogating system in an optically coupled arrangement. The device may be combined with an insulin-infusion system.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: April 10, 2018
    Assignee: Medtronic MiniMed, Inc.
    Inventors: Eric Allan Larson, Voltaire Isaac Lebron, Kevin Holz, Jasson Rodriguez, Ameya Kantak, Soren Aasmul
  • Patent number: 9848805
    Abstract: A new biostable glucose permeable polymer has been developed which is useful, for example, in implantable glucose sensors. This biostable glucose permeable polymer has a number of advantageous characteristics and, for example, does not undergo hydrolytic cleavage and degradation, thereby providing a composition that facilitates long term sensor stability in vivo. The versatile characteristics of this polymer allow it to be used in a variety of contexts, for example to form the body of an implantable glucose sensor. The invention includes the polymer composition, sensor systems formed from this polymer composition, and methods for making and using such sensor systems.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 26, 2017
    Assignee: Medtronic MiniMed, Inc.
    Inventors: Tri T. Dang, Henrik Egesborg, Jakob Janting, Rajiv Shah, Daniel Aaskov, Joseph F. Hall, Soren Aasmul
  • Publication number: 20170215775
    Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.
    Type: Application
    Filed: March 30, 2017
    Publication date: August 3, 2017
    Inventors: RAJIV SHAH, JESPER SVENNING KRISTENSEN, KATHERINE T. WOLFE, SOREN AASMUL, ANUBHUTI BANSAL
  • Publication number: 20170172471
    Abstract: A new biostable glucose permeable polymer has been developed which is useful, for example, in implantable glucose sensors. This biostable glucose permeable polymer has a number of advantageous characteristics and, for example, does not undergo hydrolytic cleavage and degradation, thereby providing a composition that facilitates long term sensor stability in vivo. The versatile characteristics of this polymer allow it to be used in a variety of contexts, for example to form the body of an implantable glucose sensor. The invention includes the polymer composition, sensor systems formed from this polymer composition, and methods for making and using such sensor systems.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 22, 2017
    Applicant: Medtronic MiniMed, Inc.
    Inventors: Tri T. Dang, Henrik Egesborg, Jakob Janting, Rajiv Shah, Daniel Aaskov, Joseph F. Hall, Soren Aasmul
  • Patent number: 9642568
    Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: May 9, 2017
    Assignee: MEDTRONIC MINIMED, INC.
    Inventors: Rajiv Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
  • Patent number: 9421287
    Abstract: Medical devices are typically sterilized in processes used to manufacture such products and their sterilization by exposure to radiation is a common practice. Radiation has a number of advantages over other sterilization processes including a high penetrating ability, relatively low chemical reactivity, and instantaneous effects without the need to control temperature, pressure, vacuum, or humidity. Unfortunately, radiation sterilization can compromise the function of certain components of medical devices. For example, radiation sterilization can lead to loss of protein activity and/or lead to bleaching of various dye compounds. Embodiments of the invention provide methods and materials that can be used to protect medical devices from unwanted effects of radiation sterilization.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: August 23, 2016
    Assignee: Medtronic Minimed, Inc.
    Inventors: Jesper Svenning Kristensen, Soren Aasmul